# Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation

> **NCT03746301** · — · COMPLETED · sponsor: **Bayer** · enrollment: 924 (actual)

## Conditions studied

- Non-valvular Atrial Fibrillation (NVAF)

## Interventions

- **DRUG:** Rivaroxaban(Xarelto,BAY 59-7939)

## Key facts

- **NCT ID:** NCT03746301
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-03
- **Primary completion:** 2021-07-28
- **Final completion:** 2021-12-15
- **Target enrollment:** 924 (ACTUAL)
- **Last updated:** 2022-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03746301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03746301, "Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03746301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*